Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
Ikea recreates Doja Cat's avant
Judge orders community service, fine for North Dakota lawmaker tied to building controversy
Arrow McLaren selects Pourchaire as replacement driver for the injured Malukas
Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
Arrow McLaren selects Pourchaire as replacement driver for the injured Malukas
Naomi Osaka is in a good place mentally. And her clay game is improving as she heads back to Paris
Court rejects Hunter Biden's appeal in gun case, setting stage for trial to begin next month
Messi in and Dybala out in Argentina squad for pre
Xavier University cancels UN ambassador’s commencement speech after student outcry
Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
How to turn a supermarket bouquet into a lusher, more personalized flower arrangement